Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-95775 in Advanced Solid Tumors and Non-Hodgkin's Lymphoma
NCT04089527Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of FT-1101 in solid tumor (advanced stage), non-Hodgkin lymphoma (NHL) and basal cell carcinoma (BCC), sponsored by Celgene Corporation. Primary endpoints: Dose Limiting Toxicity, Maximum Tolerated Dose at 12 months and 2 more. Started Oct 2019; status: completed.
02
Drugs
FT-1101
03
Conditions
solid tumor (advanced stage)non-Hodgkin lymphoma (NHL)basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT04089527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04089527.